# US 2019/0316153 A1 · Targeted gene delivery for dendritic cell vaccination

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316153 A1
- Document ID: US20190316153A1
- Status: Published application
- Kind: A1
- Application number: 16/293,151
- Filed: 2019-03-05
- Published: 2019-10-17
- Earliest claimed: 2006-07-21
- Assignees: California Institute of Technology
- Applicants: California Institute of Technology
- Inventors: Pin Wang; Lili Yang; David Baltimore
- Web page: https://patentgrep.com/patent/US20190316153A1

## CPC

- C12N 15/86: Viral vectors
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/178: {Lectin superfamily, e.g. selectins}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 38/20: Interleukins [IL]
- A61K 38/2013: {IL-2}
- A61K 38/2026: {IL-4}
- A61K 38/204: {IL-6}
- A61K 38/2046: {IL-7}
- A61K 38/2086: {IL-13 to IL-16}
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5256: {expressing foreign proteins}
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C12N 2740/13045: Special targeting system for viral vectors
- C12N 2740/15041: Use of virus, viral particle or viral elements as a vector
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/15045: Special targeting system for viral vectors
- C12N 2770/36122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/36134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2810/609: positive strand RNA viruses
- C12N 2810/855: from receptors; from cell surface antigens; from cell surface determinants
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.

## Claims

### Claim at position 1

-56. (canceled)

### Claim 57

An isolated packaging cell comprising: (a) a replication defective lentiviral vector comprising an exogenous polynucleotide of interest; (b) a vector encoding an alphavirus E2 glycoprotein that specifically binds DC-SIGN; and (c) at least one plasmid encoding proteins required for lentiviral particle packaging, wherein the packaging produces a replication defective lentivirus that has increased efficiency in transducing dendritic cells expressing DC-SIGN.

### Claim 58 (depends on 57)

The packaging cell of claim 57, wherein the packaging cell is a 293 or 293T cell.

### Claim 59 (depends on 57)

The packaging cell of claim 57, wherein the replication defective lentiviral vector comprises a self-inactivating 3′ LTR.

### Claim 60 (depends on 57)

The packaging cell of claim 57, wherein the E2 alphavirus glycoprotein comprises the amino acid sequence of SEQ ID NO: 11.

### Claim 61 (depends on 57)

The packaging cell of claim 57, wherein the polynucleotide of interest encodes an antigen selected from the group consisting of a viral antigen, an HIV antigen, an HSV antigen, and a tumor antigen.

### Claim 62 (depends on 61)

The packaging cell of claim 61, wherein the antigen comprises a gag protein.

### Claim 63 (depends on 57)

A culture comprising a plurality of packaging cells of claim 57.

### Claim 64 (depends on 61)

A culture comprising a plurality of packaging cells of claim 61.
